Pharmaceutical company Futura Medical said the impact of Covid-19 had been 'limited' to date and said it had continued to make 'good progress' on regulatory submissions for its erectile dysfunction treatment in both Europe and the US. The company said regulatory submissions for its erectile dysfunction treatment, MED3000, in both Europe and the US were on track. The company also said it continued to target submission of the regulatory dossier to the FDA by the end of third quarter of 2020 for the US. At 8:17am: (LON:FUM) Futura Medical PLC share price was +0.5p at 18.75p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.